Shukui Qin, MD, PhD

Prof. Dr. Shukui Qin is the Deputy Director of People’s Liberation Army (PLA) 81 Hospital (Nanjing, China), Director of Cancer Center of Chinese PLA, and Director of National Drug Clinical Trial Agency of PLA 81 Hospital. He serves as the Executive Member of the Asian Clinical Oncology Society (ACOS), Chair of Chinese Society of Clinical Oncology (CSCO), Council Member of PLA Medical Science Commission (and the Executive Member of its oncology society), Member of the Oncology Branch of Chinese Medical Association, Expert Committee Member of National Tumor Standardized Diagnosis and Treatment of Ministry of Health (and also the leader of the Liver Cancer Expert Panel and Cancer Pain Expert Panel), Vice President of Beijing Xisike Clinical Oncology Research Foundation, and Member of Chinese Anti-cancer Association (CACA) (and the Vice Chairman of the Committee of Rehabilitation and Palliative Care affiliated to CACA). After decades of clinical practice and scientific research, Dr. Qin has accumulated rich experiences in the medical treatment of gastrointestinal cancers and their bone metastases. Dr Qin has published over 400 articles in peer-reviewed journals and 44 scientific books. He has been granted numbers of professional awards at the ministerial and provincial levels (including four first-class prizes, two second-class prizes,seven third-class prizes, and two fourth-class prizes). He enjoys special allowance from State Council of China and the PLA. Currently he is the Editor-in-Chief of two highly rated journals (Journal of Clinical Oncology and Clinical Oncology Tribune) in China.

Jiade J. Lu, MD, MBA

Dr. Lu obtained his Medical Doctor (M.D.) from the Medical School of the State University of New York at Buffalo, USA, and his M.B.A. from both the University of California, Los Angeles and the National University of Singapore. He completed his residency training in radiation oncology at University of Miami Jackson Memorial Hospital. After his specialty training, Dr. Lu started his academic career at the Department of Radiation Oncology at the National University Cancer Institute of Singapore (NCIS). In 2010, he was appointed the Head of the Department of Radiation Oncology of the National University Hospital/NCIS. In 2012, he was appointed the Vice Chairman of Medical Board of the National University Hospital (Research). In February 2014, he accepted the appointment by the Shanghai Municipal Government, and started his endeavor as the Executive President of the newly established Shanghai Proton and Heavy Ion Center.

Dr. Lu is active in clinical practice as well as academic activity. In addition to his busy clinical and research work in head and neck cancers, he has edited and published 8 oncology texts or reference books, contributed to over 25 book chapters, and close to 100 original articles in international peer-reviewed journals. With the help from his colleagues, Dr. Lu started the Journal of Radiation Oncology in 2012.

Dr. Lu had served a number of international publishing and publicly listed corporations as advisor or independent board member of the board of directors.

Education

M.D. (Medicine) from the State University of New York at Buffalo

M.B.A. from University of California, Los Angeles

M.B.A. from the National University of Singapore 

B.S. (Biochemistry) from the State University of New York at Buffalo

Wenyin Shi

Dr Wenyin Shi is a board-certified radiation oncologist who specializes in the treatment of CNS malignancies, benign brain tumor, lymphoma, skin cancer, and sarcoma. He received his medical degree from Shanghai Medical College, Fudan University(former Shanghai Medical University), and PhD degree from University of Florida studying biomedical sciences (Cancer Biology). He completed radiation oncology residency from University of Florida. He has been a faculty at Thomas Jefferson University after residency. He is currently an associate professor at Department of Radiation Oncology, Thomas Jefferson University. He is the medical director for Radiation Oncology at Jefferson Hospital for Neuroscience. He is the co-director for Jefferson Brain Tumor Center, and Radiation Oncology Director for Jefferson Cutaneous Lymphoma Center.

His research focuses on innovative clinical trials incorporating novel therapeutic agents with radiation, including molecular targeting, anti-angiogenic, and immune checkpoint agents. He has been principal investigator of multiple investigator initiated trials. He also focuses on radiation technology innovations, particularly radiosurgery, and stereotactic body radiotherapy. He has published over 70 peer-reviewed manuscripts, and 8 book chapters. He has been named “Castle Connolly top doctors” since 2015.